drugset / Trial / NCT07037758
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.
Timeline
- Start
- 2025-09-16
- Primary completion
- 2028-03-18
- Completion
- 2031-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarlatamab | Protein / enzyme biologic | — | Intravenous |
| Subject | etakafusp alfa | Protein / enzyme biologic | — | Intravenous |